Literature DB >> 22331300

The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol.

Arjun Saha1, Chinmoy Sarkar, Satya P Singh, Zhongjian Zhang, Jeeva Munasinghe, Shiyong Peng, Goutam Chandra, Eryan Kong, Anil B Mukherjee.   

Abstract

Disruption of the blood-brain barrier (BBB) is a serious complication frequently encountered in neurodegenerative disorders. Infantile neuronal ceroid lipofuscinosis (INCL) is a devastating childhood neurodegenerative lysosomal storage disorder caused by palmitoyl-protein thioesterase-1 (PPT1) deficiency. It remains unclear whether BBB is disrupted in INCL and if so, what might be the molecular mechanism(s) of this complication. We previously reported that the Ppt1-knockout (Ppt1-KO) mice that mimic INCL manifest high levels of oxidative stress and neuroinflammation. Recently, it has been reported that CD4(+) T-helper 17 (T(H)17) lymphocytes may mediate BBB disruption and neuroinflammation, although the precise molecular mechanism(s) remain unclear. We sought to determine: (i) whether the BBB is disrupted in Ppt1-KO mice, (ii) if so, do T(H)17-lymphocytes underlie this complication, and (iii) how might T(H)17 lymphocytes breach the BBB. Here, we report that the BBB is disrupted in Ppt1-KO mice and that T(H)17 lymphocytes producing IL-17A mediate disruption of the BBB by stimulating production of matrix metalloproteinases (MMPs), which degrade the tight junction proteins essential for maintaining BBB integrity. Importantly, dietary supplementation of resveratrol (RSV), a naturally occurring antioxidant/anti-inflammatory polyphenol, markedly reduced the levels of T(H)17 cells, IL-17A and MMPs, and elevated the levels of tight junction proteins, which improved the BBB integrity in Ppt1-KO mice. Intriguingly, we found that RSV suppressed the differentiation of CD4(+) T lymphocytes to IL-17A-positive T(H)17 cells. Our findings uncover a mechanism by which T(H)17 lymphocytes mediate BBB disruption and suggest that small molecules such as RSV that suppress T(H)17 differentiation are therapeutic targets for neurodegenerative disorders such as INCL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331300      PMCID: PMC3335311          DOI: 10.1093/hmg/dds038

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  37 in total

1.  Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL.

Authors:  Zhongjian Zhang; Yi-Ching Lee; Sung-Jo Kim; Moonsuk S Choi; Pei-Chih Tsai; Yan Xu; Yi-Jin Xiao; Peng Zhang; Alison Heffer; Anil B Mukherjee
Journal:  Hum Mol Genet       Date:  2005-12-20       Impact factor: 6.150

2.  Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.

Authors:  P Gupta; A A Soyombo; A Atashband; K E Wisniewski; J M Shelton; J A Richardson; R E Hammer; S L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 3.  Storage solutions: treating lysosomal disorders of the brain.

Authors:  Mylvaganam Jeyakumar; Raymond A Dwek; Terry D Butters; Frances M Platt
Journal:  Nat Rev Neurosci       Date:  2005-09       Impact factor: 34.870

4.  Transendothelial permeability changes induced by free radicals in an in vitro model of the blood-brain barrier.

Authors:  P Lagrange; I A Romero; A Minn; P A Revest
Journal:  Free Radic Biol Med       Date:  1999-09       Impact factor: 7.376

5.  Progressively reduced synaptic vesicle pool size in cultured neurons derived from neuronal ceroid lipofuscinosis-1 knockout mice.

Authors:  Tuhin Virmani; Praveena Gupta; Xinran Liu; Ege T Kavalali; Sandra L Hofmann
Journal:  Neurobiol Dis       Date:  2005-11       Impact factor: 5.996

Review 6.  Matrix metalloproteinases in neuroinflammation.

Authors:  Gary A Rosenberg
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

7.  Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Ellen Bible; Praveena Gupta; Sandra L Hofmann; Jonathan D Cooper
Journal:  Neurobiol Dis       Date:  2004-07       Impact factor: 5.996

8.  Multiple sclerosis: serial study of gadolinium-enhanced MR imaging.

Authors:  R I Grossman; B H Braffman; J R Brorson; H I Goldberg; D H Silberberg; F Gonzalez-Scarano
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

Review 9.  Current state of clinical and morphological features in human NCL.

Authors:  Hans H Goebel; Krystyna E Wisniewski
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

10.  Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis.

Authors:  J Vesa; E Hellsten; L A Verkruyse; L A Camp; J Rapola; P Santavuori; S L Hofmann; L Peltonen
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

View more
  23 in total

1.  Prospects for stem cell therapy in neuronal ceroid lipofuscinosis.

Authors:  Michael C Kruer; David A Pearce; Paul J Orchard; Robert D Steiner
Journal:  Regen Med       Date:  2013-09       Impact factor: 3.806

2.  Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine.

Authors:  Rozzy Finn; Attila D Kovács; David A Pearce
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

Review 3.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

4.  Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Jie Hu; Jui-Yun Lu; Andrew M S Wong; Linda S Hynan; Shari G Birnbaum; Denis S Yilmaz; Barbara M Streit; Ewelina M Lenartowicz; Thomas C M Thompson; Jonathan D Cooper; Sandra L Hofmann
Journal:  Mol Genet Metab       Date:  2012-05-22       Impact factor: 4.797

5.  Resveratrol attenuates the blood-brain barrier dysfunction by regulation of the MMP-9/TIMP-1 balance after cerebral ischemia reperfusion in rats.

Authors:  Haidong Wei; Shiquan Wang; Luming Zhen; Qianzi Yang; Zhixin Wu; Xiaoming Lei; Jianrui Lv; Lize Xiong; Rongliang Xue
Journal:  J Mol Neurosci       Date:  2014-10-21       Impact factor: 3.444

Review 6.  Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).

Authors:  Jacqueline A Hawkins-Salsbury; Jonathan D Cooper; Mark S Sands
Journal:  Biochim Biophys Acta       Date:  2013-06-06

7.  Cln1 gene disruption in mice reveals a common pathogenic link between two of the most lethal childhood neurodegenerative lysosomal storage disorders.

Authors:  Goutam Chandra; Maria B Bagh; Shiyong Peng; Arjun Saha; Chinmoy Sarkar; Matthew Moralle; Zhongjian Zhang; Anil B Mukherjee
Journal:  Hum Mol Genet       Date:  2015-07-09       Impact factor: 6.150

8.  Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Authors:  Sondra W Levin; Eva H Baker; Wadih M Zein; Zhongjian Zhang; Zenaide M N Quezado; Ning Miao; Andrea Gropman; Kurt J Griffin; Simona Bianconi; Goutam Chandra; Omar I Khan; Rafael C Caruso; Aiyi Liu; Anil B Mukherjee
Journal:  Lancet Neurol       Date:  2014-07-02       Impact factor: 44.182

9.  Expression of the Nrf2-system at the blood-CSF barrier is modulated by neonatal inflammation and hypoxia-ischemia.

Authors:  Barbara D'Angelo; C Joakim Ek; Mats Sandberg; Carina Mallard
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

Review 10.  Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs).

Authors:  Nihar Kinarivala; Paul C Trippier
Journal:  J Med Chem       Date:  2015-11-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.